How to Read Clinical Trial Results

1. Start with the protocol, not the headline

Before reading the result, reconstruct what the study was designed to prove. The strongest sources are the trial registry, the protocol or statistical-analysis plan when available, prior company disclosures and peer-reviewed publications. The press release should then be compared with those prespecified commitments.

ClinicalTrials.gov can help identify study type, enrollment, arms, masking, primary and secondary outcomes, timing and eligibility criteria. It is indispensable, but it is not perfect: records may be updated late, and the registry may not contain every analytical detail. Use it alongside the complete company release, presentation and any regulator or journal material.

2. What the clinical phases are designed to answer

Phase labels are useful shorthand, but they are not guarantees of size, quality or success. Oncology, rare-disease, vaccine and gene-therapy programs can use designs that differ from the textbook pattern. The FDA describes the phases broadly as follows: Phase 1 generally emphasizes safety and dosage, Phase 2 explores effectiveness and side effects, Phase 3 confirms benefit and monitors adverse reactions in larger populations, and Phase 4 gathers information after approval.

3. Trial design determines what the result can prove

Randomization

Random allocation aims to balance known and unknown patient characteristics across treatment groups. Without randomization, differences in disease severity, prior treatment or prognosis may create the appearance of benefit. Single-arm studies can be appropriate in some settings, especially when disease history is predictable and the effect is dramatic, but comparisons with historical controls require caution.

Control group

The comparator may be placebo, standard of care, an active drug, best supportive care or a physician’s choice. A result is only interpretable relative to that comparator. Beating placebo may not establish commercial differentiation if effective therapies already exist. Conversely, a noninferiority study against a strong standard may be valuable if the new drug is safer, easier to use or suitable for a broader population.

Blinding

Blinding reduces the risk that patients, investigators or assessors influence subjective outcomes. It matters especially for symptoms, pain, behavior and clinician-scored measures. Open-label designs are not automatically invalid, but they require greater attention to objective endpoints and independent assessment.

Eligibility criteria

Inclusion and exclusion rules define the population to which the result applies. A highly selected group may produce cleaner data but limit real-world relevance. Compare age, disease stage, prior therapies, biomarker status, organ function and geographic mix with the patients likely to receive the drug commercially.

Sample size and statistical power

Power is the probability that the study will detect a prespecified effect if that effect truly exists. A small study may miss a real effect or produce an unstable estimate. A very large study can make a small effect statistically significant even if the clinical benefit is modest. The planned effect size, variability, event rate and dropout assumptions all matter.

Interim analyses and stopping rules

Some trials allow early stopping for efficacy, futility or safety. Properly designed interim analyses adjust statistical thresholds to preserve the overall false-positive rate. When a company reports an interim result, check whether it was prespecified, who reviewed it and whether enrollment or follow-up continued.

4. Primary, secondary and exploratory endpoints

Endpoints define success before the data are known. Their hierarchy is fundamental because testing many outcomes creates opportunities for chance findings.

Clinical endpoints versus surrogate endpoints

A clinical endpoint measures how a patient feels, functions or survives. A surrogate is a marker expected to predict clinical benefit, such as a laboratory value, imaging measure or pathological response. Some surrogates are well established; others remain uncertain. A large biomarker change may be scientifically interesting but commercially or regulatorily limited if the link to patient benefit is weak.

Composite endpoints

A composite combines several events—death, hospitalization and urgent intervention, for example. Examine which component drives the result. A statistically successful composite dominated by a less important or subjective component can be less persuasive than the headline suggests.

5. Statistics without the fog

P-value

A p-value measures how incompatible the observed data are with a specified null hypothesis under the assumptions of the analysis. It is not the probability that the drug works, the probability that the result will replicate or the size of the benefit. A small p-value can accompany a clinically trivial effect; a larger p-value can occur when a meaningful effect is estimated imprecisely in a small trial.

Effect size

Effect size is the magnitude of the difference. It may be an absolute change, relative reduction, difference in means, odds ratio, risk ratio or hazard ratio. Always translate the result into patient terms where possible. A relative reduction can sound dramatic while the absolute benefit is small when the baseline event rate is low.

Confidence interval

A confidence interval describes the precision of the estimate under repeated-sampling logic. A narrow interval suggests a more precise estimate; a wide interval means substantial uncertainty. Check whether the interval includes no effect, clinically unimportant effects or both benefit and harm.

Multiplicity

Testing many endpoints, doses, time points and subgroups increases the chance of a false-positive finding. Prespecified statistical hierarchies, alpha allocation and other adjustment methods address this problem. When the primary endpoint fails, apparently positive secondary findings may become descriptive rather than confirmatory.

Missing data

Dropouts and missing observations can bias results, particularly when discontinuation differs between arms or relates to efficacy and toxicity. Look for the amount of missing data, the reason it is missing and the sensitivity analyses used. “Evaluable patients” may exclude people whose outcomes were unfavorable or unavailable; understand why.

6. Common clinical metrics

7. Analysis populations: who is included?

The same trial can produce different estimates depending on who is counted and how treatment changes are handled.

• Intent-to-treat (ITT): generally includes participants according to randomized assignment, preserving the benefit of randomization.
• Modified ITT: excludes participants according to a defined rule. Read the rule carefully.
• Per-protocol: includes participants who sufficiently followed the protocol; useful for some questions but vulnerable to selection bias.
• Safety population: often includes patients who received at least one dose.
• Efficacy-evaluable population: may require follow-up or assessments. Understand every exclusion.

8. Subgroups and post-hoc analyses

Subgroups may reveal biology, identify a responsive population or explain heterogeneity. They can also generate false positives because many slices of the data are examined. Stronger subgroup evidence is prespecified, biologically plausible, adequately sized, internally consistent and supported by an interaction test or independent replication.

Be cautious when the overall trial is negative but the investment thesis shifts immediately to one favorable subgroup. That result may justify another study; it rarely erases the failure of the original hypothesis by itself.

9. Reading safety as seriously as efficacy

Safety must be interpreted in the context of disease severity, expected benefit, treatment duration and available alternatives. A toxicity acceptable in refractory cancer may be unacceptable for a chronic condition treated for years.

Exposure matters

A safety profile based on short exposure in 30 patients cannot establish long-term safety in thousands. Compare patient-years, treatment duration and dose intensity. Rare events may appear only when a therapy is used broadly.

10. How to read a topline press release

1. Find the exact primary-endpoint sentence. Separate the company’s description from the numerical result.
2. Locate the treatment effect and uncertainty. Record both absolute and relative measures where available.
3. Check every required endpoint. Co-primary and hierarchical rules can make the success definition more complex.
4. Identify the analysis population and denominator. Compare randomized, treated and evaluable counts.
5. Review secondary endpoints in order. Determine which are confirmatory, nominal or exploratory.
6. Read the safety paragraph word for word. “Generally well tolerated” is a conclusion, not a table.
7. Record the data cutoff and follow-up. Early data can look different after maturation.
8. Compare with the protocol and prior guidance. Note changed endpoints, timing or populations.
9. Compare with standard care and competitors. A result has no commercial meaning in isolation.
10. List what was not disclosed. Missing information can be as important as the released data.

11. Worked example: a fictional randomized trial

Imagine a fictional company, Northstar Therapeutics, reporting a Phase 2 trial of an oral therapy for a chronic autoimmune disease. Two hundred forty patients were randomized equally to drug or placebo for 24 weeks. The primary endpoint was the proportion achieving a prespecified clinical response at week 24.

The headline

The company announces that the study met its primary endpoint with a response rate of 58% on drug versus 43% on placebo, p=0.021. The headline is positive. The absolute difference is 15 percentage points; the relative improvement is about 35%. Those measures communicate different impressions, so both should be considered.

The precision

Suppose the confidence interval for the absolute difference is 2 to 28 percentage points. The result excludes no difference at the prespecified confidence level, but the interval remains wide. The true benefit could be modest or substantial. A larger confirmatory study would be needed to refine the estimate.

The secondary outcomes

The first key secondary endpoint, a patient-reported symptom score, misses its threshold. Under the hierarchical plan, later endpoints are nominal even if their p-values are below 0.05. A press release that lists those later numbers without explaining the hierarchy would risk overstating confirmatory evidence.

The safety profile

Grade 3 liver-enzyme elevations occur in 6% of treated patients and 1% of placebo patients, with several treatment discontinuations. The events resolve after stopping therapy. Whether that risk is acceptable depends on efficacy, monitoring burden and available alternatives. It may also affect dose selection and the eventual label.

The market interpretation

The fair conclusion is not simply “trial succeeded” or “trial failed.” The study provides proof of concept on the primary endpoint, but patient-reported benefit is uncertain and the liver signal requires attention. The asset may deserve a higher probability of technical success while its peak penetration or commercial convenience is revised downward. That mixed interpretation is often closer to reality than the binary headline.

12. From clinical result to market reaction

Markets react to the difference between the result and the expectation bar. A statistically strong result can disappoint if efficacy is weaker than competitors, safety prevents broad use or the valuation already assumes dominance. A mixed result can rally if the market expected failure and the data preserve a credible path forward.

13. Red flags in trial communications

• The release leads with an exploratory endpoint while the primary result is buried.
• Percentages are reported without patient counts or denominators.
• Only relative benefit is shown when absolute benefit is small.
• A negative overall trial is reframed around an unplanned subgroup.
• “Statistically significant” appears without effect size or confidence interval.
• Safety is summarized with adjectives but no event rates.
• The data cutoff is old or follow-up differs substantially between patients.
• The company changes the analysis population without a clear explanation.
• Comparator performance is unusual and not discussed.
• The regulatory plan becomes vaguer after the readout.

14. The complete trial-results checklist

15. Bottom line

Good clinical analysis begins before the readout, with the protocol and prespecified success criteria. It continues beyond the p-value to effect size, precision, safety, durability and real-world relevance. The goal is not to find a reason to agree with the headline; it is to determine exactly what the data add, what they fail to answer and which assumptions should change.

Chapter 3 follows the evidence into the regulatory process: NDA and BLA reviews, PDUFA target dates, priority review, advisory committees, manufacturing, labeling, approval, extensions and Complete Response Letters.